economic returns to investment in aids treatment in low and middle income countries投资经济效益在低收入和中等收入国家的艾滋病治疗.pdfVIP

Economic Returns to Investment in AIDS Treatment in Low and Middle Income Countries 1 2,3 4 2 5 5 Stephen Resch *, Eline Korenromp , John Stover , Matthew Blakley , Carleigh Krubiner , Kira Thorien , Robert Hecht5, Rifat Atun2,6 1 Harvard School of Public Health, Center for Health Decision Science, Boston, Massachusetts, United States of America, 2 The Global Fund to Fight AIDS, Tuberculosis and Malaria, Geneva, Switzerland, 3 Department of Public Health, University Medical Center, Rotterdam, The Netherlands, 4 Futures Institute, Glastonbury, Connecticut, United States of America, 5 Results for Development Institute, Washington, District of Columbia, United States of America, 6 Imperial College, London, United Kingdom Abstract Since the early 2000s, aid organizations and developing country governments have invested heavily in AIDS treatment. By 2010, more than five million people began receiving antiretroviral therapy (ART) – yet each year, 2.7 million people are becoming newly infected and another two million are dying without ever having received treatment. As the need for treatment grows without commensurate increase in the amount of available resources, it is critical to assess the health and economic gains being realized from increasingly large investments in ART. This study estimates total program costs and compares them with selected economic benefits of ART, for the current cohort of patients whose treatment is cofinanced by the Global Fund to Fight AIDS, Tuberculosis and Malaria. At end 2011, 3.5 million patients in low and middle income countries will be receiving ART through treatment programs cofinanced by the Global Fund. Using 2009 ART prices and program costs, we estimate that t